Search results
Results from the WOW.Com Content Network
Empagliflozin/metformin was approved for use in the European Union in May 2015. [5] Empagliflozin/metformin was approved for use in the United States in August 2015. [6] [11] The extended release version was approved for use in the United States in December 2016. [12] [13] Empagliflozin/metformin was approved for use in Australia in May 2020. [2]
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a survey of more ...
A recall has been ordered for a high-profile diabetes drug after producers discovered it contained alarmingly high levels of a cancer-causing impurity. Marksans Pharma Limited has recalled ...
AstraZeneca’s Farxiga drug, which treats chronic kidney disease, heart failure and Type 2 diabetes, was among the 10 medications selected last year for the initial round of price negotiations ...
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
Metformin has seen widespread use in Europe since the 1950s but wasn’t approved by the FDA to be used in the U.S. until 1995, according to a 2021 article by Harvard Medical School.